Match!
Elizabeth Garrett-Mayer
Medical University of South Carolina
CancerOncologyImmunologyCancer researchMedicine
297Publications
46H-index
9,583Citations
What is this?
Publications 301
Newest
#1Anvesh R. Kompelli (MUSC: Medical University of South Carolina)H-Index: 2
#2Kathleen B. Cartmell (MUSC: Medical University of South Carolina)H-Index: 9
Last. Terry A. Day (MUSC: Medical University of South Carolina)H-Index: 34
view all 10 authors...
Abstract Objective Racial disparities have been well characterized and African American (AA) patients have 30% lower 5-year survival rates than European Americans (EAs) for head and neck squamous carcinoma (HNSCC). This poorer survival can be attributed to a myriad of different factors. The purpose of this study was to characterize AA-EA similarities and differences in sociodemographic, lifestyle, clinical, and psychosocial characteristics in HNSCC patients near the time of surgery. Methods Sett...
Source
#1Kelsey A Klute (UNMC: University of Nebraska Medical Center)H-Index: 3
#2Elizabeth Garrett-Mayer (MUSC: Medical University of South Carolina)H-Index: 46
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 9 authors...
122Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort o...
Source
#1Ranju Gupta (Lehigh Valley Hospital)H-Index: 1
#2Elizabeth Garrett-Mayer (MUSC: Medical University of South Carolina)H-Index: 46
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 10 authors...
132Background: TAPUR is a phase II basket trial evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort o...
Source
#1Matthew J. Carpenter (MUSC: Medical University of South Carolina)H-Index: 29
#2Amy E. Wahlquist (MUSC: Medical University of South Carolina)H-Index: 14
Last. Brent M. Egan (Greenville Health System)H-Index: 50
view all 8 authors...
Source
#1Sheba Goklany (ASU: Arizona State University)H-Index: 5
#2Ping Lu (MUSC: Medical University of South Carolina)H-Index: 11
Last. Kaushal Rege (ASU: Arizona State University)H-Index: 24
view all 7 authors...
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a death ligand that can preferentially induce apoptosis in cancer cells over normal cells. The transmembrane form of TRAIL has been shown to elicit much stronger activity than its soluble counterpart but delivery is a potential challenge. Here, we investigated the potential of aminoglycoside-derived polymers to enhance delivery of a plasmid (pEF-TRAIL) that expresses the transmembrane form of TRAIL in order to determine the effec...
Source
#1Lourdes M. Nogueira (MUSC: Medical University of South Carolina)H-Index: 6
#2Clare E Burton (MUSC: Medical University of South Carolina)
Last. Victoria J. Findlay (MUSC: Medical University of South Carolina)H-Index: 18
view all 9 authors...
In the US, African American women have a significantly higher rate of mortality due to breast cancer compared to Caucasian American women. Molecular differences in tumor biology exist between racial groups; however, their contribution to cancer disparity is not well understood. Our studies have identified a race-specific, mechanistic link between microRNA-204 and the IGF2R. The IGF2R is a tumor suppressor gene in several cancers including breast cancer and IGF2R levels are found at significantly...
#1Ricardo H. AlvarezH-Index: 6
Last. Richard L. SchilskyH-Index: 66
view all 12 authors...
Source
Last. Richard L. SchilskyH-Index: 66
view all 15 authors...
Source
#1R. Donald Harvey (Emory University)H-Index: 21
#2Wendy S. Rubinstein (American Society of Clinical Oncology)H-Index: 2
Last. Suanna S. Bruinooge (American Society of Clinical Oncology)H-Index: 15
view all 17 authors...
LBA108Background: Restrictive trial eligibility criteria limit data generalizability and patient opportunity to participate. We compared numbers and characteristics of patients (pts) eligible using...
Source
#1Eugene R AhnH-Index: 2
#2Pam K. MangatH-Index: 2
Last. Richard L. SchilskyH-Index: 66
view all 20 authors...
9041Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort ...
12345678910